CRNO B — Cereno Scientific AB Share News
0.000.00%
Last trade - 00:00- SEK1.11bn
- SEK1.25bn
Brief: Cereno Scientific Reports Positive Results In Phase II Study Of CS1 In Rare Disease Pulmonary Arterial Hypertension
Brief: Cereno Signs CRO To Conduct Phase I Study Of Drug Candidate CS014
Brief: Cereno Scientific Q2 Result After Financial Items Swings To Profit SEK 10.7 Mln
Brief: Cereno Scientific Q2 Adjusted EPS at SEK -0.05
Brief: Cereno Scientific Appoints Eva Jagenheim As CFO
Brief: Cereno's Chair Joakim Söderström Purchases 1,240,000 Shares In Co
Brief: Cereno Scientific Says Co And Abbott Enter Collaboration For Use Of Cutting-Edge Monitor Device In Upcoming Phase II Study With Cs1
Brief: Cereno Scientific Q4 Loss After Financial Items At SEK 5 109 959
Brief: Cereno Scientific Gets Patent In Japan
Brief: Cereno Scientific Signs CRO For Phase II Study With Drug Candidate CS1 In Rare Disease PAH
Brief: Cereno Scientific Q3 Pretax Loss SEK 3.1 Million
Brief: Cereno Scientific AB Says First Day For Trading For Warrants Of Series To1 And To2 Respectively Has Been Set For October 14, 2020
Brief: Cereno Scientific Completes Directed Issue Of About SEK 60 Mln
Brief: Cereno Scientific AB Says To Carry Out Directed Issue Of Units With Total Issue Proceed Of Approximately Sek 60 Million
Brief: Cereno Scientific Q2 Loss After Financial Items SEK 4.0 Mln
Brief: Cereno Scientific Starts Cooperation With University Of Michigan
Brief: Cereno Scientific Q1 Loss After Financial Items SEK -3,752,667
Brief: Cereno Scientific's Phase II Clinical Trial Postponed Due To COVID-19
Brief: Cereno Scientific Signs Agreement With Inorbit Therapeutics